ClinicalTrialsFinder
RecruitingPhase 1Phase 2NCT04445454

Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection

Sponsor

University of Liege

Enrollment

20 participants

Start Date

Jun 12, 2020

Study Type

INTERVENTIONAL

Conditions

Coronavirus Infection

Summary

The overall objective of the study is to evaluate the safety and efficacy of MSC therapy combined with best supportive care in hospitalized patients with COVID-19.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Mesenchymal stromal cells for people with coronavirus infection. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALMesenchymal stromal cells

Bone marrow collection and MSC expansion cultures will be carried out at the Laboratory of Cell and Gene Therapy (LTCG) at the University of Liège as described in IMPD and its SOPs.

Locations(1)

CHU de Liège

Liège, Belgium

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04445454

Related Trials

ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers

NCT043678571 location

Post COVID-19 Biorepository

NCT048855041 location

Capturing MultiORgan Effects of COVID-19

NCT045100251 location

Convalescent Plasma Collection and Treatment in Pediatrics and Adults

NCT043760341 location